What is aTyr Pharma Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, aTyr Pharma's Probability of Financial Distress (%) is 0.16%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of aTyr Pharma's Probability of Financial Distress (%)
For the Biotechnology subindustry, aTyr Pharma's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Probability of Financial Distress (%) falls into.
aTyr Pharma Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -6.45 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.16% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
aTyr Pharma (aTyr Pharma) Business Description
Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
| Sanjay Shukla |
officer: Chief Medical Officer |
C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121 |
| Paul Schimmel |
director |
88 SIDNEY ST, CAMBRIDGE MA 02139 |
| Jill Marie Broadfoot |
officer: Chief Financial Officer |
3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| Sara Zaknoen |
director |
C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
| John K Clarke |
director |
C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542 |
| Nancy Krueger |
officer: See Remarks |
C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| Svetlana Lucas |
director |
3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| Jane A Gross |
director |
2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
| John Mendlein |
director, officer: CEO and Executive Chairman |
|
| Ecor1 Capital Fund Qualified, L.p. |
10 percent owner |
357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
| Ashraf Amanullah |
officer: Vice President, Manufacturing |
C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| John T Blake |
officer: Vice President, Finance |
C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342 |
| Timothy P Coughlin |
director |
339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
| Jeffrey S. Hatfield |
director |
11080 ROSELLE STREET, SAN DIEGO CA 92121 |
| David John King |
officer: See Remarks |
3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
aTyr Pharma (aTyr Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIFE has been successfully added to your